Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Commentary · June 21, 2022

Impact of a Third Anti–SARS-CoV-2 mRNA Dose on Seropositivity in Patients With Lymphoma or CLL



Additional Info

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
Haematologica 2022 Jun 01;107(6)1454-1459, M Kohn, M Delord, M Chbat, A Guemriche, F Merabet, AL Roupie, N Lombion, H Farhat, T Longval, A Cabannes-Hamy, J Lambert, S Marque-Juillet, V Raggueneau, J Osman, M Spentchian, S Rigaudeau, P Rousselot, C Besson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading